Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update Life Science Investing
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update Life Science Investing
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease Life Science Investing
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting Life Science Investing
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Life Science Investing
NRx Pharmaceuticals, Inc. to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 Life Science Investing
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 Life Science Investing
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting Life Science Investing
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 Life Science Investing